CHF
Switzerland, Francs
Interest expense
Interest expense
Schedule of Consolidated Statement of Comprehensive Income or Loss
Schedule Of Consolidated Statement Of Comprehensive Income or Loss Of Entities Party To Deed Of Cross Guarantee [Table Text Block]
Schedule Of Consolidated Statement Of Comprehensive Income or Loss Of Entities Party To Deed Of Cross Guarantee
Charged to profit or loss
Other Provisions Charged To Profit (Loss)
The amount of other provisions charged to profit (loss).
Purchases of property, plant and equipment
Purchase of property, plant and equipment, classified as investing activities
Grant date August 26, 2024
Grant Date August 26, 2024 [Member]
Grant Date August 26, 2024
Telix Pharmaceuticals International Holdings Pty Ltd
Telix Pharmaceuticals International Holdings Pty Limited [Member]
The name of the entity which is controlled by another entity.
Salaries and wages
Wages and salaries
Telix Targeting Technology
Telix Targeting Technology [Member]
Telix Targeting Technology
Entity File Number
Entity File Number
Schedule of Finance Costs
Disclosure Of Detailed Information About Finance Costs [Text Block]
The disclosure of detailed information about finance costs.
Disclosure of detailed information about business combination [line items]
Disclosure of detailed information about business combination [line items]
Impairments
Impairment loss recognised in profit or loss, intangible assets other than goodwill
Deferred tax benefit
Deferred tax
Deferred tax expense (income)
Levels of fair value hierarchy [domain]
Levels of fair value hierarchy [domain]
Grand Pharma strategic partnership [Abstract]
Grand Pharma strategic partnership [Abstract]
Grand Pharma strategic partnership [Abstract]
Inter-segment eliminations
Inter-segment R&D
Elimination of intersegment amounts [member]
Grant date May 22, 2024
Grant Date May 22, 2024 [Member]
Grant Date May 22, 2024
Schedule of Reconciliation of Liabilities Arising from Financing Activities
Disclosure of reconciliation of liabilities arising from financing activities [text block]
Telix Pharmaceuticals (Belgium) SRL
Telix Pharmaceuticals (Belgium) SRL [Member]
The name of the entity which is controlled by another entity.
6-12 months
Later than six months and not later than one year [member]
Sundry items
Other tax effects for reconciliation between accounting profit and tax expense (income)
Changes in the fair value of investments at fair value through other comprehensive income
Other comprehensive income, net of tax, gains (losses) from investments in equity instruments
Schedule of Right-of-Use Assets
Disclosure of quantitative information about right-of-use assets [text block]
Fair value measurement
Description of accounting policy for fair value measurement [text block]
Payments for investments in financial assets
Purchase of financial instruments, classified as investing activities
Disclosure of detailed information about borrowings [table]
Disclosure of detailed information about borrowings [table]
Volume weighted average price (in dollars per share)
Volume Weighted Average Price Of Equity Instruments
The 10-day volume weighted average price of other equity instruments.
Intangible assets
Beginning balance
Ending balance
Intangible assets and goodwill
Statement of comprehensive income
Statement of comprehensive income [abstract]
Statement of changes in equity [line items]
Statement of changes in equity [line items]
Total comprehensive (loss)/income for the year attributable to:
Comprehensive income attributable to [abstract]
Basic (loss)/earnings per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)
Basic (loss)/earnings per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share)
Basic earnings (loss) per share from continuing operations
Value of Shareholding [Abstract]
Value of Shareholding [Abstract]
Value of Shareholding
Total secured borrowings current
Secured Borrowings, Current
long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
Maximum borrowing facility
Debt Instrument, Maximum Borrowing Facility
The amount of maximum borrowing facilities that may be available for operating activities and to settle capital commitments.
Change in assets and liabilities
Change in assets and liabilities [Abstract]
Change in assets and liabilities [Abstract]
Acquisition of businesses
Increase Through Business Combinations, Lease Liabilities
The amount of lease liabilities increased through acquisition of business.
Research and development costs [Abstract]
Research And Development Costs [Abstract]
Research and development costs [Abstract]
Proceeds from issue of bonds, notes and debentures
Proceeds from issue of bonds, notes and debentures
Shares allocated to employees
Shares Allocated To Employees, Value
Amount of shares allocated to employees.
Contingent or deferred consideration
Contingent Or Deferred Consideration As Of Acquisition Date
Contingent Or Deferred Consideration As Of Acquisition Date
Acquisition of businesses
Acquisitions through business combinations, intangible assets and goodwill
Current
Current [member]
Prepayments
Current prepayments
Exchange differences
Increase (decrease) through net exchange differences, intangible assets and goodwill
Statement of financial position [abstract]
Statement of financial position [abstract]
Number
Number Of Options [Abstract]
Number of options [Abstract]
Significant changes in the current reporting period
Description Of Accounting Policy For Significant Changes In The Current Reporting Period [Policy Text Block]
The description of the entity's material accounting policy information for significant changes in the current or prior reporting period.
Cover [Abstract]
Cover [Abstract]
Maximum
Maximum [Member]
Telix Pharmaceuticals (Singapore) Pte Ltd
Telix Pharmaceuticals (Singapore) Pte Ltd [Member]
The name of the entity which is controlled by another entity.
Consideration received
Consideration received in contract liabilities
The amount of an entity's obligation to transfer goods or services to a customer for which the entity has received consideration.
Remeasurement of provisions
Tax Effect Of Remeasurement Of Provisions
The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to remeasurement of provisions.
Net investment in subsidiaries
Net Investment in Subsidiaries
Net Investment in Subsidiaries
Provisions
Description of accounting policy for provisions [text block]
Classes of intangible assets other than goodwill [axis]
Classes of intangible assets other than goodwill [axis]
Trade receivables
Trade receivables
Additional upfront paid
Upfront Cash Transferred As Of Acquisition Date
Upfront Cash Transferred As Of Acquisition Date
Entity Shell Company
Entity Shell Company
Cash flows from financing activities
Cash flows from (used in) financing activities [abstract]
Current unsecured convertible bonds
Current bonds issued and current portion of non-current bonds issued
Contract liabilities [abstract]
Contract liabilities [abstract]
Classes of liabilities [domain]
Classes of liabilities [domain]
Contingent consideration
Non-current
Non-Current Contingent Consideration
The non-current portion of non-current contingent consideration.
Total comprehensive (loss)/income for the year
Comprehensive income
Diluted (loss)/earnings per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share)
Diluted earnings (loss) per share from continuing operations
-10%
Ten Percent Decrease [Member]
Ten Percent Decrease
Work in progress
Current work in progress
Basis of preparation
Disclosure of basis of preparation of financial statements [text block]
Total secured borrowings non current
Secured Borrowings, Non Current
The amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.
Phase 3
Phase 3 [Member]
Phase 3
Document Fiscal Period Focus
Document Fiscal Period Focus
Sales taxes and Goods and Services Tax (GST)
Description of accounting policy for taxes other than income tax [text block]
Total assets
Assets
Approval for marketing authorization probability success factor
Approval For Marketing Authorization Probability Success Factor [Member]
This member stands for approval for marketing authorization probability success factor used as a measurement input.
Recognized amounts of identifiable assets acquired and liabilities assumed
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Income tax
Description of accounting policy for income tax [text block]
RLS
RLS [Member]
RLS
Corporate information [Abstract]
Corporate Information [Abstract]
Corporate information [Abstract]
Lapsed/forfeited during the year (in AUD/USD per share)
Weighted Average Exercise Price Of Share Options Expired And Forfeited In Share-Based Payment Arrangement
The weighted average exercise price of share options expired and forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]
Associates [domain]
Associates [domain]
Cost of Sales
Cost of sales [member]
Business combinations
Description of accounting policy for business combinations [text block]
Credit risk
Credit risk [member]
Trading Symbol
Trading Symbol
Contingent consideration [Abstract]
Contingent Consideration [Abstract]
Contingent consideration [Abstract]
At a point in time
Goods or services transferred at point in time [member]
Total revenue from continuing operations
Revenue
Disclosure of detailed information about business combination [abstract]
Disclosure of detailed information about business combination [abstract]
Due later than one year
Non-current Borrowings Over Payments
The non-current portion of non-current borrowings(overpayments).
Entity Address, City or Town
Entity Address, City or Town
Unrealized currency gain/(loss)
Unrealized Foreign Exchange Gains (Losses)
The amount of unrealized foreign exchange losses (gains).
Schedule of Lease Liabilities
Disclosure Of Information About Lease Liabilities [Text Block]
The disclosure of information about lease liabilities.
Borrowings
Disclosure of borrowings [text block]
IT infrastructure, hosting and support
Information Technology Infrastructure Hosting And SupportExpenses
The amount of expense recognised on information technology infrastructure, hosting and support services.
Share capital
Issued capital [member]
ABX-CRO
ABX-CRO [Member]
An entity associated with one or more key management personnel of the reporting entity.
Borrowings
Total borrowings current
Due within one year
Current
Current borrowings
Beginning balance
Ending balance
Reserve of gains and losses on financial assets measured at fair value through other comprehensive income
Other non-current liabilities
Other non-current liabilities
Other non-current liabilities, carrying amount
Other non-current liabilities
Classes of other provisions [domain]
Classes of other provisions [domain]
Facility limit
Borrowing Facilities, Maximum Borrowing Capacity
Borrowing Facilities, Maximum Borrowing Capacity
Other reserves
Other reserves [member]
HSBC Bank Australia Limited
HSBC Bank Australia Limited [Member]
This member stands for the name of financial institution which company made loan agreement.
Schedule of Key Management Personnel Compensation
Disclosure of information about key management personnel [text block]
Net cash inflow/(outflow)
Increase (decrease) through financing cash flows, liabilities arising from financing activities
Trade and other receivables
Trade And Other Receivables Recognized As Of Acquisition Date
The amount recognized as of the acquisition date for trade and other receivables acquired in a business combination.
Disclosure of quantitative information about right-of-use assets [table]
Disclosure of quantitative information about right-of-use assets [table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Total unsecured borrowings current
Unsecured Borrowings, Current
long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.
Purchases of other non-current assets
Purchase of other long-term assets, classified as investing activities
Brussels South and Sacramento
Brussels South and Sacramento [Member]
This member stands for a product or business unit.
Number of shares issued upon exercise of each convertible security (in shares)
Number Of Shares Issued Upon Exercise Of Each Convertible Security
Number of shares issued upon exercise of each convertible security under Equity Incentive Plan.
Trade and other payables
Description of accounting policy for trade and other payables [text block]
Corporate Information
Disclosure of general information about financial statements [text block]
Reclassifications
Increase (decrease) through transfers, property, plant and equipment
TLX300-CDx
TLX300-CDx [Member]
TLX300-CDx
Prima-facie tax at a rate of 30.0% (2023: 30.0%, 2022: 30.0% )
Tax expense (income) at applicable tax rate
Pre-commercial
Pre-Commercial [Member]
Pre-Commercial
Rhine Pharma GmbH
Rhine Pharma GmbH (formerly Telix Pharmaceuticals (Germany) GmbH) [Member]
The name of the entity which is controlled by another entity.
Manufacturing and distribution costs
Disclosure Of Manufacturing And Distribution Costs [Text Block]
Disclosure Of Manufacturing And Distribution Costs
Construction in progress
Construction in progress [member]
TLX591-Px (Illuccix®)
TLX591-C Dx (Illuccix) [Member]
This member stands for a product or business unit.
Assets
Assets [abstract]
Precision Medicine
Precision Medicine [Member]
This member stands for a segment which deals with is a medical model that separates people into different groups-with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. This segment focus on Commercial sales of Illuccix and other diagnostic products subsequent to obtaining regulatory approvals. This segment also includes the development activities of the Group's diagnostic pipeline.
Right-of-use assets
Right-of-use assets [member]
90 days
Later than three months and not later than four months [member]
Types of antidilutive instruments [axis]
Types of antidilutive instruments [axis]
Share price at grant date (in AUD per share)
Weighted average share price, share options granted
Current assets
Current assets [abstract]
Liabilities Related to Contracts with Customers
Explanation of significant changes in contract assets and contract liabilities [text block]
Other creditors
Other current payables
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Fair value adjustments
Additional disclosures for amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Non-current assets
Non-current assets [abstract]
Disclosure of information for cash-generating units [abstract]
Disclosure of information for cash-generating units [abstract]
Finance costs
Disclosure of finance cost [text block]
Other advisory services
Auditor's remuneration for other services
Disclosure of nature and extent of risks arising from financial instruments [line items]
Disclosure of nature and extent of risks arising from financial instruments [line items]
General and administration costs
General and administration costs
General and administrative expense
Cash and cash equivalents
Cash and cash equivalents recognised as of acquisition date
Temporary differences in relation to share-based payments
Share Based Payments [Member]
This member stands for share based payments.
Tranche [Axis]
Tranche [Axis]
Tranche
Income tax expense/(benefit)
Disclosure of income tax [text block]
Document Information [Line Items]
Document Information [Line Items]
Reclassifications
Increase (decrease) through transfers, intangible assets and goodwill
Revenue
Description of accounting policy for recognition of revenue [text block]
Purchases of various goods and services from entities controlled by key management personnel
Key Management Personnel, Purchases Of Goods And Services Related Party Transactions
The amount of compensation to key management personnel in the form of purchases of goods and services.
Disclosure of defined benefit plans [abstract]
Disclosure of defined benefit plans [abstract]
Unrecognized income tax benefit
Unused Tax Losses And Credits For Which No Deferred Tax Asset Is Recognised
Unused Tax Losses And Credits For Which No Deferred Tax Asset Is Recognised
Telix Pharmaceuticals (US) Inc.
Telix Pharmaceuticals (US) Inc. [Member]
The name of the entity which is controlled by another entity.
Payments for deferred consideration
Payments Of Deferred Consideration, Classified As Investing Activities
Payments Of Deferred Consideration, Classified As Investing Activities
Schedule of Number and Weighted Average Exercise Price of Stock Options
Disclosure of number and weighted average exercise prices of share options [text block]
Capital commitments [abstract]
Capital commitments [abstract]
Software
Computer software [member]
Receivables from contracts with customers [abstract]
Receivables from contracts with customers [abstract]
Loan amount
Current payables to related parties
Unwind of discount
Increase through adjustments arising from passage of time, other provisions
Total fair value adjustments
Fair Value Adjustments Recognized As Of Acquisition Date
Net amount of increase (decrease) in assets and liabilities for fair value adjustment in a business combination.
Schedule of Other Non-current Assets
Schedule Of Other Noncurrent Assets [Table Text Block]
Schedule Of Other Noncurrent Assets
Share-based payments reserve
Reserve of share-based payments [member]
Cash flows from investing activities
Cash flows from (used in) investing activities [abstract]
(Decrease)/Increase in provisions
Adjustments For Increase (Decrease) In Provisions
Adjustments for increase (decrease) in provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.
Loan balance
Borrowings Over Payments
The amount of outstanding funds that the entity is obligated to repay.
Risk-free rate
Risk free interest rate, share options granted
Payments for contingent consideration (Investing)
Payments For Contingent Consideration, Classified As Investing Activities
Payments For Contingent Consideration, Classified As Investing Activities
Payments for contingent consideration (Operating)
Payments For Contingent Consideration, Classified As Operating
Payments For Contingent Consideration, Classified As Operating
Material accounting policy information [Abstract]
Material Accounting Policy Information [Abstract]
Material accounting policy information [Abstract]
Number of shares outstanding (in shares)
Number of instruments or interests issued or issuable
Cash and cash equivalents
Description of accounting policy for determining components of cash and cash equivalents [text block]
Set-off of deferred tax assets pursuant to set-off provisions
Deferred Tax Assets Pursuant To Set-Off Provisions
The increase (decrease) in deferred tax liabilities pursuant to set-off provisions.
Detailed information about contingent consideration [Table]
Detailed Information About Contingent Consideration [Table]
Detailed information about contingent consideration [Table]
Share-based payments to employees
Increase (decrease) through share-based payment transactions, equity
Decommissioning liability
Provision for decommissioning, restoration and rehabilitation costs
Lease liabilities [abstract]
Lease liabilities [abstract]
QSAM
QSAM Biosciences, Inc [Member]
The name of the entity which is controlled by another entity.
Total non-current assets
Non-current assets
Non-current assets
Exchange differences on translation of foreign operations
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
Customer relationships
Fair Value Adjustment, Customer Relationships
Amount of increase (decrease) in customer relationships for fair value adjustment in a business combination.
+10%
Ten Percent Increase [Member]
Ten Percent Increase
Reconciliation of changes in other provisions [abstract]
Reconciliation of changes in other provisions [abstract]
Schedule of Statement of Financial Position
Schedule Of Financial Position, Separate Financial Statements [Text Block]
Schedule Of Financial Position, Separate Financial Statements
TLX300
TLX300-Tx [Member]
This member stands for a product or business unit.
Number of products developed
Number Of Products Developed
Number Of Products Developed
Other (gains)/losses (net)
Disclosure of other operating income (expense) [text block]
Classes of property, plant and equipment [axis]
Classes of property, plant and equipment [axis]
Impairment of assets
Description of accounting policy for impairment of assets [text block]
Performance Rights exercised (in shares)
Number Of Performance Right Exercised In Share-Based Payment Arrangement
Number Of Performance Right Exercised In Share-Based Payment Arrangement
Cash-generating units [axis]
Cash-generating units [axis]
Convertible bonds
Non-current convertible bonds
Non-current portion of non-current bonds issued
Classes of property, plant and equipment [domain]
Classes of property, plant and equipment [domain]
Other gains/(losses)(net)
Other (losses)/gains (net)
Other losses/(gains) (net)
Total other losses/(gains) (net)
Other gains (losses)
Entity Address, Country
Entity Address, Country
Working capital facility
Working Capital Facility [Member]
Working Capital Facility
Reconciliation of changes in intangible assets other than goodwill [abstract]
Reconciliation of changes in intangible assets other than goodwill [abstract]
Unwind of working capital facility costs
Unwind of Working Capital Facility Costs
Unwind of Working Capital Facility Costs
Total unsecured borrowings non current
Unsecured Borrowings, Non-Current
The amount of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
EUR
Euro Member Countries, Euro
Unwind of discount on contingent consideration liabilities
Unwind Of Discount On Contingent Consideration Liabilities
The amount of unwind of discount on contingent consideration liabilities.
Net foreign exchange differences
Effect of exchange rate changes on cash and cash equivalents
Foreign currency translation
Description of accounting policy for foreign currency translation [text block]
Transaction costs of borrowings or capital raising
Payments for debt issue costs
Change in risk variable, percent
Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent
Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent
Document Annual Report
Document Annual Report
GST receivables
Current receivables from taxes other than income tax
Contract liabilities
Contract liabilities
Non-current contract liabilities
Reconciliation of Contingent Consideration [Roll Forward]
Reconciliation of Contingent Consideration [Roll Forward]
Reconciliation of Contingent Consideration
Geographical areas [domain]
Geographical areas [domain]
Lease liabilities
Description Of Accounting Policy For Lease Liabilities [Policy Text Block]
The description of the entity's material accounting policy information for lease liabilities.
Other non-current assets
Disclosure of other non-current assets [text block]
Trade and other receivables
Trade and other current receivables
Patents, trademarks, licenses and customer contracts
Patents, Trademarks, Licenses And Customer Contracts [Member]
This member stands for a class of intangible assets representing patents, trademarks, licenses and customer contracts.
Financial risk management
Disclosure of financial risk management [text block]
Entity Interactive Data Current
Entity Interactive Data Current
Other current assets
Current assets recognised as of acquisition date
BNP Paribas and IMBC Group
BNP Paribas and IMBC Group [Member]
This member stands for the name of financial institution which company made loan agreement.
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities
Disclosure of attribution of expenses by nature to their function [line items]
Disclosure of attribution of expenses by nature to their function [line items]
Levels of fair value hierarchy [axis]
Levels of fair value hierarchy [axis]
Schedule of Contingent Consideration Valuation
Schedule Of Contingent Consideration Valuation [Text Block]
Tabular disclosure of information about contingent consideration valuation.
Other research and development projects
Other Research And Development Projects [Member]
This member stands for pre-clinical expenses and research expenditure on novel targets and technologies.
Schedule of General and Administration Costs
Disclosure Of Detailed Information About General And Administration Costs Explanatory [Table Text Block]
The disclosure of detailed information about general and administrative costs.
Finance costs
Finance costs
Finance costs
Finance costs
Schedule of Financial Assets
Disclosure of financial assets [text block]
Acquisition of businesses
Acquisitions through business combinations, property, plant and equipment
Disclosure of credit risk exposure [table]
Disclosure of credit risk exposure [table]
Material accounting policy information
Disclosure of material accounting policy information [text block]
HSBC Bank Australia Ltd
HSBC Bank Australia Ltd [Member]
This member stands for the name of financial institution which company made loan agreement.
Other current assets
Disclosure of other current assets [text block]
Schedule of Maturity Analysis for Borrowings From Lenders
Disclosure Of Detailed Information About Maturity Analysis For Borrowings From Lenders [Text Block]
The disclosure of maturity analysis for borrowings from lenders.
Non-current secured working capital facility
Secured Working Capital Facility, Non-Current
The non-current portion of non-current secured working capital facility received.
Surplus of foreign currency receivables and financial assets over payables
Surplus Of Foreign Currency Receivables And Financial Assets Over Payables
The amount of foreign currency receivables and financial assets exceeding the amount of payables.
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:
Tax effect of amounts which are not deductible (taxable) in calculating taxable income [Abstract]
Tax effect of amounts which are not deductible (taxable) in calculating taxable income [Abstract]
Research and development services
Revenue From Research And Development Services
The amount of income arising from research and development services.
Royalty income
Royalty income
Therapeia GmbH & Co. KG
Therapeia GmbH & Co. KG [Member]
The name of the entity which is controlled by another entity.
Entity Central Index Key
Entity Central Index Key
Balance at beginning (in shares)
Balance at ending (in shares)
Number of share options outstanding in share-based payment arrangement
Professional fees
Professional fees expense
Valuation techniques used in fair value measurement [axis]
Valuation techniques used in fair value measurement [axis]
TLX101
TLX101-Tx
TLX101-Tx [Member]
This member stands for a product or business unit.
Reconciliation of changes in deferred tax liability (asset) [abstract]
Reconciliation of changes in deferred tax liability (asset) [abstract]
Acquisition transaction costs
Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination
Basic earnings per share [Abstract]
Basic earnings per share [abstract]
(Loss)/profit for the year attributable to:
Profit (loss), attributable to [abstract]
Increase in trade creditors
Adjustments For Decrease (Increase) In Trade Creditors
Adjustments for decrease (increase) in trade creditors to reconcile profit (loss) to net cash flow from (used in) operating activities.
Net loss of combined entity as if combination occurred at beginning of period
Profit (loss) of combined entity as if combination occurred at beginning of period
Equity
Risk exposure associated with instruments sharing characteristic
Current secured working capital facility
Secured Working Capital Facility, Current
The amount of current secured working capital facility current received and the current portion of non-current secured working capital facility current received.
Property, plant and equipment [Abstract]
Reconciliation of changes in property, plant and equipment [abstract]
Entity Filer Category
Entity Filer Category
Discounted cash flow
Discounted cash flow [member]
Number of loan agreements
Number Of Loan Agreements
The number of loan agreements.
Milestone payment on receipt of second marketing approval
Milestone Payment On Receipt Of Second Marketing Approval
Amount of milestone payment on receipt of second marketing approval.
Additions
Additions other than through business combinations, property, plant and equipment
Rent and insurance
Rent And Insurance Costs
The amount of expenses relating to rent and insurances.
Operating profit
Profit (loss) from operating activities
Telix Pharma Japan KK
Telix Pharma Japan KK [Member]
The name of the entity which is controlled by another entity.
Foreign currency risk [Abstract]
Foreign Currency Risk [Abstract]
Foreign currency risk [Abstract]
Other receivables
Other current receivables
Unwind of discount
Unwind of discount in contract liabilities
The amount of unwind of discount in contract liabilities.
Audit or review of financial statements
Auditor's remuneration for audit services
Percentage of reasonably possible decrease in unobservable input, liabilities
Percentage of reasonably possible decrease in unobservable input, liabilities
Entity Address, Address Line One
Entity Address, Address Line One
Tax losses and tax credits
Tax Losses And Tax Credits [Member]
This member stands for tax losses and tax credits.
Right-of-use assets
Lease liabilities
Disclosure of leases [text block]
TLX400-Tx
TLX400-Tx [Member]
TLX400-Tx
Other income
Other Miscellaneous Gain/(Loss)
Other Miscellaneous Gain/(Loss)
Product Development
Product Development [Member]
This member stands for an reporting segment of the entity which developing radiopharmaceutical products for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services.
Sale of goods
Revenue from sale of goods
Disclosure Of Parent Entity Financial Information [Abstract]
DisclosureOfParentEntityFinancialInformationAbstract [Abstract]
Telix Pharmaceuticals (ANZ) Pty Ltd
Telix Pharmaceuticals (ANZ) Pty Ltd [Member]
The name of the entity which is controlled by another entity.
Increase in employee benefit obligations
Adjustments for increase (decrease) in employee benefit liabilities
Deferred tax assets [Abstract]
Deferred tax assets [Abstract]
Deferred tax assets [Abstract]
Schedule of Share Based Compensation Expense
Explanation of effect of share-based payments on entity's profit or loss [text block]
Provisions
Disclosure of provisions [text block]
Statement of cash flows [abstract]
Statement of cash flows [abstract]
Grant date October 18, 2023
Grant Date October 18, 2023 [Member]
Grant Date October 18, 2023
Number of Shares [Abstract]
Number of Shares [Abstract]
Number of Shares
Default financial statements date
Default financial statements date [member]
Discounted expected future cash flows period
Discounted Expected Future Cash Flows Period
The period used for discounting the expected future cash flows for each program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
A one year delay in commercialization
One Year Delay In Commercialization [Member]
One Year Delay In Commercialization
Definite
Definite Useful Life [Member]
Definite Useful Life
Radiopharmacy operations
Radiopharmacy Operations [Member]
Radiopharmacy Operations
Germany
GERMANY
WAEP
Weighted Average Exercise Price [Abstract]
Weighted average exercise price [Abstract]
Difference in overseas tax rates
Tax effect of foreign tax rates
Restricted cash
Non-current restricted cash and cash equivalents
IsoTherapeutics
ISO Therapeutics Group, LLC [Member]
This member stands for a business combination.
Disclosure of products and services [line items]
Disclosure of products and services [line items]
Schedule of Useful Economic Lives of Acquisition Related Intangible Assets
Schedule of Useful Economic Lives Of Acquisition Related Intangible Assets [Table Text Block]
Schedule of Useful Economic Lives Of Acquisition Related Intangible Assets
Remeasurement of contingent consideration
Remeasurement of contingent consideration
Gains (Losses) From Remeasurement Of Contingent Consideration
The remeasurement amount of contingent consideration during the year.
Travel, conferences and entertainment
Travel Conferences And Entertainment Costs
The amount of expense recognised on travel, conferences and entertainment activities.
Government grant liability
Government grant liability
Government Grant Liability [Member]
This member stands for government grant liability aggregated categories of financial liabilities.
Total increase (decrease) in equity
Increase (decrease) in equity
Current liabilities
Current liabilities [abstract]
Brazil
BRAZIL
Remeasurement of contingent consideration
Remeasurement Of Contingent Consideration Adjustment
Remeasurement Of Contingent Consideration Adjustment
Customer relationships
Customer-related intangible assets [member]
Impairments/(impairment reversals) of intangible assets
Impairment Loss (Impairment Reversals) Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill
The amount of impairment loss (impairment reversals) of intangible assets.
Borrowing costs incurred
Transaction costs
Borrowing costs incurred
Disclosure of transactions between related parties [line items]
Disclosure of transactions between related parties [line items]
Increase (decrease) in recoverable amount of CGU
Increase (Decrease) in Recoverable Amount Of Asset Or Cash-Generating Unit
Increase (Decrease) in Recoverable Amount Of Asset Or Cash-Generating Unit
Amortization of intangible assets
Amortisation expense
Other comprehensive (loss)/income:
Other comprehensive income [abstract]
Investment in Mauna Kea Technologies
Mauna Kea Technologies [Member]
This member stands for announced a strategic investment in Mauna Kea to develop new hybrid pharmaceutical-device products through the combination of Telix's cancer-targeting agents with Mauna Kea's surgical endomicroscopy platform.
Canada
CANADA
Treasury shares acquired (in shares)
Increase (Decrease) Through Treasury Shares Acquired
The increase (decrease) in equity resulting from treasury share transactions.
Borrowings lender [Abstract]
Borrowings lender [Abstract]
Borrowings lender [Abstract]
Switzerland
SWITZERLAND
Temporary differences
Temporary differences [member]
Total financial liabilities
Non-derivative financial liabilities, undiscounted cash flows
Classes of share capital [domain]
Classes of share capital [domain]
Schedule of Number of Options Issued under Equity Incentive Plan Outstanding
Disclosure of terms and conditions of share-based payment arrangement [text block]
TheraPharm
TheraPharm [Member]
This member stands for transactions or other events in which an acquirer obtain control of business.
Exchange differences
Increase (Decrease) In Foreign Exchange Differences In Convertible Bonds
Increase (Decrease) In Foreign Exchange Differences In Convertible Bonds
China
CHINA
Transfer on satisfaction of acquisition performance rights
Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights, Equity
Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights, Equity
Australia
AUSTRALIA
Finance income
Finance income
Document Shell Company Report
Document Shell Company Report
Disclosure of maturity analysis for non-derivative financial liabilities [abstract]
Disclosure of maturity analysis for non-derivative financial liabilities [abstract]
Dedicaid
Dedicaid GmbH [Member]
The name of the entity which is controlled by another entity.
Customer rebates payable
Customer Rebates Payable
Customer Rebates Payable
Realized currency gain
Realized Currency Gains (Losses)
The amount of realized currency exchange (losses) gains.
Disclosure of other provisions [line items]
Disclosure of other provisions [line items]
Additions
Additions to right-of-use assets
Grant date October 24, 2022
Grant Date October 24, 2022 [Member]
Grant Date October 24, 2022
Payments for acquisition of subsidiaries, net of cash acquired
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
Belgium
BELGIUM
Conversion price (in AUD per share)
Conversion Price
The conversion nominal value per share.
Beginning balance
Ending balance
Total lease liabilities
Lease liabilities, carrying amount
Lease liabilities
Financial assets [Abstract]
Disclosure of financial assets [abstract]
Percentage of major credit risk
Major Risk Threshold, Percentage Of Total Class Of Asset
The percentage of concentration of major credit risk.
Other non-cash movements
Increase (decrease) through other changes, liabilities arising from financing activities
Provisions
Non-current
Non-current provisions
Timing of transfer of goods or services [axis]
Timing of transfer of goods or services [axis]
Disclosure of quantitative information about right-of-use assets [abstract]
Disclosure of quantitative information about right-of-use assets [abstract]
QSAM Therapeutics Inc.
QSAM Therapeutics Inc. [Member]
The name of the entity which is controlled by another entity.
Liabilities arising from financing activities [domain]
Liabilities arising from financing activities [domain]
Unwind of discount on convertible bonds
Unwind Of Discount On Convertible Bonds
The amount of unwind of discount on convertible bonds during the year.
Schedule of Share-based Payment Reserve
Disclosure of number and weighted average exercise prices of other equity instruments [text block]
Grant date July 6, 2023
Grant Date July 6, 2023 [Member]
Grant Date July 6, 2023
Trade and other receivables
Description of accounting policy for trade and other receivables [text block]
Share capital
Beginning balance
Ending balance
Share capital
Issued capital
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, after tax, liabilities
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, after tax, liabilities
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Intangible assets
Disclosure of intangible assets and goodwill [text block]
Changes in provisions
Increase (Decrease) From Change In Provisions, Property, Plant And Equipment
The amount of change in provisions of property, plant and equipment.
Issue of shares on exercise of options
Increase (decrease) through exercise of options, equity
Inventory Type [Axis]
Inventory Type [Axis]
Inventory Type
Timing of transfer of goods or services [domain]
Timing of transfer of goods or services [domain]
Exercise price (in AUD/USD per share)
Exercise price, share options granted
Beginning balance (in shares)
Ending balance (in shares)
Number of shares outstanding
Audit Information [Abstract]
Audit Information
Products and services [axis]
Products and services [axis]
Products and services [axis]
Total financial liabilities, carrying amount
Financial liabilities
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in other comprehensive income, after tax, assets
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in other comprehensive income, after tax, assets
Dedicaid, QDOSE
Dedicaid QDOSE [Member]
This member stands for a product or business unit.
Other
Other temporary differences [member]
Schedule of Depreciation Charge on Right-of-Use Assets
Depreciation Charge On Right-Of-Use Assets [Text Block]
The disclosure of depreciation charge on right-of-use assets.
Income tax (expense)/benefit
Income tax expense/(benefit)
Income tax expense
Tax expense (income)
Cash flow information
Disclosure of cash flow statement [text block]
Cash-generating units [domain]
Cash-generating units [domain]
Events occurring after the reporting period
Disclosure of events after reporting period [text block]
Change In Key Assumption [Axis]
Change In Key Assumption [Axis]
Change In Key Assumption
Maximum measurement period (in years)
Maximum Measurement Period
The maximum period of measurement from the date of acquisition to the date the group obtains complete information about facts and circumstances that existed as of the acquisition date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Document Transition Report
Document Transition Report
Percentage of credit risk
Significant Credit Risk Exposure, Risk Percentage
The percentage of concentration of credit risk.
Cash flows from operating activities
Cash flows from (used in) operating activities [abstract]
Document Period End Date
Document Period End Date
Lightpoint Surgical Ltd
Lightpoint Surgical Ltd [Member]
The name of the entity which is controlled by another entity.
Disclosure of classes of share capital [line items]
Disclosure of classes of share capital [line items]
Unwind of discount on contract liabilities
Unwind Of Discount On Contract Liabilities
The amount of unwind of discount on contract liabilities.
Exchange differences
Increase (decrease) through net exchange differences, right-of-use assets
Unwind of discount on provisions
Unwind Of Discount On Provisions
The amount of unwind of discount on provisions.
Maturity [axis]
Maturity [axis]
R&D commitments
Research and developments commitments contractual obligations
The amount of research and developments commitments contractual obligations for which the entity has committed.
United Kingdom
UNITED KINGDOM
Convertible bonds
Convertible Bonds [Member]
This member stands for convertible bonds.
Remeasurement of provisions
Increase (Decrease) Through Remeasurement, Other Provisions
Increase (Decrease) Through Remeasurement, Other Provisions
Classes of financial instruments [axis]
Classes of financial instruments [axis]
Total goodwill allocated to CGUs
Goodwill
Grant Date [Domain]
Grant Date [Domain]
Grant Date [Domain]
Associates [axis]
Associates [axis]
Bank fees
Bank and similar charges
Document Type
Document Type
Share-based payment charge
Expense from share-based payment transactions with employees
Product and Service [Axis]
Product and Service [Axis]
Spain
SPAIN
Impairments/(impairment reversals) of intangible assets
Adjustments For Impairment(Reversal) Of Intangible Assets
The amount of impairment(reversal) recognized in profit or loss for intangible assets.
Financial assets at FVOCI reserve
Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]
Expected sales volumes
Expected Sales Volume [Member]
This member stands for expected sales volume used as a measurement input.
Lease liabilities
Gross lease liabilities
Intellectual property
Brand name
Brand names [member]
Licenses of intellectual property
Revenue From Licenses Of Intellectual Property
The amount of revenue arising from licenses of intellectual property.
Grant date May 2, 2023
Grant Date May 2, 2023 [Member]
Grant Date May 2, 2023
Profit or loss [abstract]
Profit or loss [abstract]
Contract liabilities
Current
Current contract liabilities
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Customer relationships and brands
Customer Relationships And Brands [Member]
This member stands for a class of intangible assets representing customer relationships and brands.
Revenue of combined entity as if combination occurred at beginning of period
Revenue of combined entity as if combination occurred at beginning of period
Telix Pharmaceuticals (Corporate) Pty Ltd
Telix Pharmaceuticals (Corporate) Pty Limited [Member]
The name of the entity which is controlled by another entity.
Type Of Intangibles [Domain]
Type Of Intangibles [Domain]
Type Of Intangibles [Domain]
Classes of assets [axis]
Classes of assets [axis]
Measurement period adjustments
Increase (Decrease) Through Measurement Period Adjustments, Intangible Assets And Goodwill
Increase (Decrease) Through Measurement Period Adjustments, Intangible Assets And Goodwill
Trade payables
Trade payables
Operating segments
Operating segments [member]
Provisions
Current
Current provisions
Types of share-based payment arrangements [domain]
Types of share-based payment arrangements [domain]
Revenue of acquiree since acquisition date
Revenue of acquiree since acquisition date
France
FRANCE
Earnings per share [abstract]
Earnings per share [abstract]
Range [axis]
Range [axis]
Components of equity [axis]
Components of equity [axis]
Telix Pharmaceuticals (Innovations) Pty Ltd
Telix Pharmaceuticals (Innovations) Pty Ltd [Member]
The name of the entity which is controlled by another entity.
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Milestone payment on completion of phase III pivotal registration trial
Milestone Payment On Completion Of Phase III Pivotal Registration Trial
Amount of milestone payment on completion of Phase III pivotal registration trial.
Non-refundable upfront payment received
Non refundable upfront payment received
The amount of the non-refundable upfront payment received.
(Loss)/profit before income tax
(Loss)/profit before income tax
Profit (loss) before tax
Fair value (in AUD/USD per share)
Fair Value, Stock Options Granted
Fair value of share options granted during the period.
Right-of-use assets
Right-Of-Use Assets Recognized As Of Acquisition Date
The amount recognized as of the acquisition date for right-of-use assets acquired in a business combination.
Equity
Disclosure of share capital, reserves and other equity interest [text block]
Technical services
Technical Services [Member]
Technical Services
Categories of related parties [domain]
Categories of related parties [domain]
Other current assets
Total other current assets
Other current assets
Schedule of Remuneration of Auditor
Disclosure Of Detailed Information About Remuneration Of Auditor [Table Text Block]
The disclosure of detailed information about remuneration of auditor.
Disclosure of other provisions [table]
Disclosure of other provisions [table]
Percentage of reasonably possible increase in unobservable input, liabilities
Percentage of reasonably possible increase in unobservable input, liabilities
Contingent consideration payments classified as operating
Adjustments For Decrease (Increase In Contingent Consideration Payments, Classified As Operating Activities
Adjustments For Decrease (Increase In Contingent Consideration Payments, Classified As Operating Activities
Sales commissions
Sales Commissions
The amount of expense arising from sales commissions.
Classes of financial instruments [domain]
Classes of financial instruments [domain]
Disclosure of detailed information about business combination [table]
Disclosure of detailed information about business combination [table]
Deferred consideration
Deferred Consideration
Deferred Consideration
Grant date March 8, 2024
Grant Date March 8, 2024 [Member]
Grant Date March 8, 2024
Entities party to deed of cross guarantee
Entities Party To Deed Of Cross Guarantee [Member]
Entities Party To Deed Of Cross Guarantee
Auditor Location
Auditor Location
The Hongkong and Shanghai Banking Corporation Limited As The Trustee For Convertible Bond Holders
The Hongkong And Shanghai Banking Corporation Limited As The Trustee For Convertible Bond Holders [Member]
This member stands for the name of financial institution which company made loan agreement.
Credited/(charged) on acquisition
Increase (decrease) through business combinations, deferred tax liability (asset)
Phase 2
Phase 2 [Member]
Phase 2
Other (gains)/losses (net) [Abstract]
Other (Gains)/Losses (Net) [Abstract]
Other (gains)/losses (net) [Abstract]
Interest received
Interest received, classified as operating activities
1-6 months
Later than one month and not later than six months [member]
Total decommissioning costs expected to be incurred
Decommissioning Costs Expected To Be Incurred
The amount of decommissioning costs expected to be incurred.
Other equity securities - value of conversion rights
Other Equity Securities Value Of Conversion Rights
The increase (decrease) in equity resulting from the conversion of performance rights.
Provision of services
Revenue from rendering of services
Products and services [domain]
Products and services [domain]
Schedule of Operating Segment Assets and Liabilities
Disclosure of operating segments [text block]
Weighted average number of ordinary shares used as the denominator in calculating basic earnings/loss per share (in shares)
Weighted average number of ordinary shares used in calculating basic earnings per share
Superannuation
Post-employment benefit expense in profit or loss
Depreciation and amortization
Disclosure of depreciation and amortisation expense [text block]
Schedule of Movements in Deferred Tax Assets and Liabilities
Disclosure of temporary difference, unused tax losses and unused tax credits [text block]
Vested during the year (in shares)
Number Of Share Options Vested In Share Based Payment Arrangement
The number of equity-based payment instruments, that vested during the reporting period.
Impairment recognized
Impairment loss recognised in profit or loss, goodwill
Disclosure of detailed information about intangible assets [table]
Disclosure of detailed information about intangible assets [table]
Other reserves
Other reserves
Other reserves
Share-based payments
Key management personnel compensation, share-based payment
Loan balance
Opening balance
Closing balance
Carrying amount
Carrying amount
Borrowings, carrying amount
Borrowings
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Early stage clinical candidates
Early Stage Clinical Candidates [Member]
Early Stage Clinical Candidates
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense [abstract]
Schedule of Inventories
Schedule Of Inventories Current [Table Text Block]
The disclosure of detailed information about inventories.
Unwind of discount
Increase Through Adjustments Arising From Passage Of Time, Contingent Consideration
Increase Through Adjustments Arising From Passage Of Time, Contingent Consideration
Grant Date October 24, 2025
Grant Date October 24, 2025 [Member]
Grant Date October 24, 2025
Grant date September 19, 2024
Grant Date September 19, 2024 [Member]
Grant Date September 19, 2024
Disclosure of information for cash-generating units [line items]
Disclosure of information for cash-generating units [line items]
Therapeia Verwaltungs-GmbH
Therapeia Verwaltungs-GmbH [Member]
The name of the entity which is controlled by another entity.
Transaction costs arising on new share issues
Increase (Decrease) In Transaction Costs Arising On New Share Issues
The increase (decrease) in equity resulting from the transaction costs arising on new share issues.
Net cash (used in)/provided by financing activities
Cash flows from (used in) financing activities
Investment in sub-lease
Investment In Sub-Lease Recognized As Of Acquisition Date
Investment In Sub-Lease Recognized As Of Acquisition Date
First installment of non reimbursable government grant received
First installment of non reimbursable government grant received
The amount of first installment of non reimbursable government grant received.
Earnings per share
Description of accounting policy for earnings per share [text block]
Transaction costs arising on new share issues (in shares)
Increase (Decrease) In Transaction Costs Arising On New Share Issued
Number of shares increase (decrease) in transaction costs arising on new share issues.
Currency Risk Exposure
Disclosure of nature and extent of risks arising from financial instruments [text block]
Entity Current Reporting Status
Entity Current Reporting Status
Net R&D tax incentive credit
Tax Effect Of Net R&D Tax Incentive Credit
The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to R&D tax incentive credit.
Deferred tax assets and liabilities
Disclosure of deferred taxes [text block]
Statement of changes in equity [table]
Statement of changes in equity [table]
Japan
JAPAN
Change In Key Assumption [Domain]
Change In Key Assumption [Domain]
Change In Key Assumption [Domain]
Disclosure of classes of share capital [abstract]
Disclosure of classes of share capital [abstract]
Therapeutics
Therapeutics [Member]
This member stands for a medical segment which deals of medicine concerned with the treatment of disease and the action of remedial agents. The Therapeutics segment focuses on the development of company core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services. This segment includes the development activities of the Group's pivotal therapeutic pipeline.
Inter-segment revenue
Inter Segment Revenue
Inter Segment Revenue
CAD
Canada, Dollars
TLX66
TLX66-Tx [Member]
This member stands for a product or business unit.
Cost of sales
Cost of sales
Cost of sales
Classes of assets [domain]
Classes of assets [domain]
Current Fiscal Year End Date
Current Fiscal Year End Date
Bottom of range
Bottom of range [member]
120 days
Later than four months [member]
Brand name
Fair Value Adjustment, Brand Name
Amount of increase (decrease) in brand names for fair value adjustment in a business combination.
Inventories
Inventory, Net [Member]
This member stands for inventory.
Categories of related parties [axis]
Categories of related parties [axis]
Disclosure of detailed information about borrowings [line items]
Disclosure of detailed information about borrowings [line items]
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Pre-clinical research and innovation
Pre-Clinical Research And Innovation [Member]
This member stands for clinical products used for therapeutic and diagnostic applications.
ARTMS
ARTMS Inc [Member]
This member stands for a business combination.
(Loss)/profit for the year
(Loss) profit for the year
(Loss)/profit from continuing operations after income tax
Profit (loss)
Financial assets
Financial assets
Financial assets
Granted during the year (in AUD/USD per share)
Weighted average exercise price of share options granted in share-based payment arrangement
Total non-current liabilities
Non-current liabilities
Total non-current liabilities
Non-current liabilities
Property, plant and equipment
Property, plant and equipment recognised as of acquisition date
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Performance Rights issued (in shares)
Number Of Performance Right Granted In Share-Based Payment Arrangement
Number of performance right granted in share-based payment arrangement.
Document Registration Statement
Document Registration Statement
Contingent liabilities
Disclosure of contingent liabilities [text block]
Segment reporting
Disclosure of entity's operating segments [text block]
Depreciation charge
Depreciation charge on right-of-use assets
Depreciation, right-of-use assets
Grant Date March 17, 2025
Grant Date March 17, 2025 [Member]
Grant Date March 17, 2025
Temporary difference, unused tax losses and unused tax credits [domain]
Temporary difference, unused tax losses and unused tax credits [domain]
Capital commitments
Capital commitments
Tranche one
Tranche One [Member]
Tranche One
Accumulated depreciation
Accumulated depreciation and amortisation [member]
Accumulated losses
Retained earnings [member]
Transaction costs arising on convertible bonds issue
Increase (Decrease) Through Transaction Costs Arising On Convertible Bonds Issue
The increase (decrease) in equity resulting from the transaction costs arising on Convertible Bonds Issue.
Borrowings [abstract]
Borrowings [abstract]
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities
Analysis of income and expense [abstract]
Percentage of cash in foreign currency
Percentage Of Cash Held In Foreign Currency
The percentage of cash held in foreign currency.
Total unrecognized deferred tax assets
Deductible temporary differences for which no deferred tax asset is recognised
Reconciliation of liabilities arising from financing activities [Abstract]
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Grant date May 22, 2024
Grant Date May 22, 2024 1 [Member]
Grant Date May 22, 2024 1
Depreciation and amortization
Depreciation and amortization
Depreciation and amortization
Depreciation and amortisation expense
Business Contact
Business Contact [Member]
GBP
United Kingdom, Pounds
Risk adjusted post tax discount rate
Discount rate used in current estimate of value in use
Liabilities
Liabilities [abstract]
Bonds issued
Bonds issued
Temporary differences in relation to inventories
Inventory, Netting [Member]
Inventory, Netting
Indemnity period (in months)
Business Combination, Indemnity Period
Business Combination, Indemnity Period
Provisions [abstract]
Provisions [abstract]
Carrying amount
Carrying amount [member]
Percentage of reasonably possible increase in unobservable input, assets
Percentage of reasonably possible increase in unobservable input, assets
Unobservable inputs [domain]
Unobservable inputs [domain]
Changes in equity [Abstract]
Changes in equity [abstract]
Short-term employee benefits
Key management personnel compensation, short-term employee benefits
Indefinite
Indefinite Useful Life [Member]
Indefinite Useful Life
Performance Rights lapsed (in shares)
Number Of Performance Right Lapsed In Share-Based Payment Arrangement
Number Of Performance Right Lapsed In Share-Based Payment Arrangement
Security Exchange Name
Security Exchange Name
New Zealand
NEW ZEALAND
Options lapsed (in shares)
Number of share options forfeited in share-based payment arrangement
ANMI
ANMI [Member]
This member stands for transactions or other events in which an acquirer obtain control of business.
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Transfer on exercise of options
Increase (Decrease) Through Transfer On Exercise Of Options, Equity
The increase (decrease) in equity resulting from the transfer on exercise of options.
Schedule of Fair Value of Grant Date Inputs for Options Granted
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]
Schedule of Unrecognized Tax Losses
Schedule Of Unrecognized Tax Losses [Table Text Block]
The disclosure of unrecognized tax losses
Non-current
Non-current provisions for employee benefits
Type Of Intangibles [Axis]
Type Of Intangibles [Axis]
Type Of Intangibles
Right-of-use assets
Balance at the beginning
Balance at the end
Right-of-use assets
Share capital reserve
Capital reserve [member]
Contact Personnel Name
Contact Personnel Name
Treasury share acquired
Purchase of treasury shares
Net assets
Net assets
Assets (liabilities)
Radiopharmaceutical Production Facility
Radiopharmaceutical Production Facility [Member]
The member stands for services of radiopharmaceutical production facility.
Manufacturing Solutions
Manufacturing Solutions [Member]
This member stands for a segment which deals with global network of facilities designed to deliver patient doses worldwide and comprises costs to operate company facilities and assets associated with the Group's vertically integrated manufacturing and supply chain.
Government grant
Government grant liability, carrying amount
Government grants
Schedule of Consolidated Statement of Financial Position
Schedule of Consolidated Statement of Financial Position [Table Text Block]
Schedule of Consolidated Statement of Financial Position
Intellectual property
Intangible assets other than goodwill [member]
Payments to suppliers and employees
Payments to suppliers for goods and services and to and on behalf of employees
Total segment adjusted EBITDA
Adjusted Earnings (Loss) Before Interest, Tax, Depreciation And Amortization
The amount of adjusted earnings before interest, tax, depreciation and amortization of the entity.
Schedule of Geographical Information
Disclosure of geographical areas [text block]
Items to be reclassified to profit or loss in subsequent periods:
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Beginning balance
Ending balance
Total contract liabilities
Contract liabilities
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Anti-dilutive shares (in shares)
Number of potential ordinary shares that are antidilutive in period presented
Schedule of Allocation of Intangible Assets to Each Cash Generating Unit
Disclosure Of Detailed Information About Intangible Assets To Each Cash Generating Unit [Table Text Block]
The disclosure of detailed information about intangible assets to each cash generating unit.
Payments for decommissioning liability
Purchase Of Decommissioning Liability, Classified As Investing Activities
The cash outflow for the purchase of decommissioning liability, classified as investing activities.
Decommissioning liability
Provision for decommissioning, restoration and rehabilitation costs [member]
Tax losses
Unused tax losses [member]
Non-current secured bank loans
Non-current portion of non-current secured bank loans received
SENSEI
SENSEI [Member]
This member stands for a product or business unit.
Foreign currency translation reserve
Reserve of exchange differences on translation [member]
Shares allocated to employees (in shares)
Increase (Decrease) Through Shares Allocated To Employees
Shares allocated to employees during the period.
U.S. listing costs
Listing Costs
The amount of expense recognised on listing costs.
Liabilities arising from financing activities [axis]
Liabilities arising from financing activities [axis]
Amounts adjusted to property, plant and equipment
New provisions, other provisions
Vested and exercisable (in shares)
Number of share options vested and exercisable in share-based payment arrangement
The number of share options fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
Current secured bank loans
Current secured bank loans received and current portion of non-current secured bank loans received
Shares issued (in shares)
Increase (Decrease) In Number Of Shares Issued
The increase (decrease) in the number of shares issued.
Useful economic life
Useful life measured as period of time, intangible assets other than goodwill
Amounts adjusted to intangible assets
Increase (Decrease) Through Adjustments to Intangible Assets, Contingent Consideration
Increase (Decrease) Through Adjustments to Intangible Assets, Contingent Consideration
Classes of share capital [axis]
Classes of share capital [axis]
Options exercised (in shares)
Exercised during the year (in shares)
Number of share options exercised in share-based payment arrangement
Singapore
SINGAPORE
Types of antidilutive instruments [domain]
Types of antidilutive instruments [domain]
Total equity
Beginning balance
Ending balance
Equity
Entity Addresses, Address Type [Axis]
Entity Addresses, Address Type [Axis]
Additional payable
Deferred Consideration Under License Agreement Recognised As Of Acquisition Date
Deferred Consideration Under License Agreement Recognised As Of Acquisition Date
Property, plant and equipment
Beginning balance
Ending balance
Property, plant and equipment
Commitments
Disclosure of commitments [text block]
Gross profit
Gross profit
Other current liabilities
Other current liabilities
Schedule of Convertible Bonds
Disclosure Of Detailed Information About Convertible Bonds Reported In Statement Of Financial Position [Table Text Block]
The disclosure of detailed information about convertible bonds reported in statement of financial position.
Types of contracts [domain]
Types of contracts [domain]
Items that will not be reclassified to profit or loss in subsequent periods:
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]
Level 1
Level 1 of fair value hierarchy [member]
Date of termination of earn-outs
Earn-Out Payments, Termination Period
The date termination on earn-out payments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
First Tranche
First Tranche [Member]
First Tranche
Grant date October 31, 2023
Grant Date October 31, 2023 [Member]
Grant Date October 31, 2023
Current
Current borrowings and current portion of non-current borrowings, by type [abstract]
EIP options issued (in shares)
Granted during the year (in shares)
Number of share options granted in share-based payment arrangement
Disclosure of detailed information about property, plant and equipment [line items]
Disclosure of detailed information about property, plant and equipment [line items]
Grant date April 5, 2022
Grant Date April 5, 2022 [Member]
Grant Date April 5, 2022
Exchange differences
Exchange differences in contract liabilities
The amount of exchange differences in contract liabilities.
Payables recognised as of acquisition date
Contingent liabilities recognised as of acquisition date
Interest paid
Interest Paid On Convertible Bonds
The cash outflow for interest paid on convertible debt, classified as operating activities.
Percentage of reasonably possible decrease in unobservable input, assets
Percentage of reasonably possible decrease in unobservable input, assets
Undrawn borrowing facilities
Undrawn borrowing facilities
Risk adjusted post-tax discount rate
Discount rate, measurement input [member]
Disclosure of non-adjusting events after reporting period [abstract]
Disclosure of non-adjusting events after reporting period [abstract]
Furniture, fittings and equipment
Fixtures and fittings [member]
Balance at beginning (in AUD/USD per share)
Balance at ending (in AUD/USD per share)
Weighted average exercise price of share options outstanding in share-based payment arrangement
Owners of Telix Pharmaceuticals Limited
Loss for the year
Profit (loss), attributable to owners of parent
Selling and marketing expenses
Selling and marketing expenses
Sales and marketing expense
Decrease in contract liabilities
Adjustments for increase (decrease) in contract liabilities
Fair value remeasurement of provisions
Adjustments for provisions
30 days
Later than one month and not later than two months [member]
Measurement period adjustments
Measurement period adjustments recognised for particular assets, liabilities, non-controlling interests or items of consideration
Total current liabilities
Current liabilities
Current liabilities
Short term incentives
Short-Term Incentives
The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.
Trade and other receivables [abstract]
Trade and other receivables [abstract]
BNP Paribas
BNP Paribas [Member]
This member stands for the name of financial institution which company made loan agreement.
Deferred tax assets
Net deferred tax assets
Deferred tax assets
Inventories
Total inventories
Current inventories
Document Accounting Standard
Document Accounting Standard
Exchange differences
Increase (Decrease) Through Exchange Differences Right Of Use Assets
The increase (decrease) in right-of-use assets resulting from net exchange differences.
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Share-based payments reserve [Abstract]
Share-Based Payments Reserve [Abstract]
Share-based payments reserve [Abstract]
Disclosure of quantitative information about right-of-use assets [line items]
Disclosure of quantitative information about right-of-use assets [line items]
Principles of consolidation
Description Of Accounting Policy For Principles Of Consolidation [Policy Text Block]
The description of the entity's accounting policy for principles of consolidation.
Statement of changes in equity [abstract]
Statement of changes in equity [abstract]
Acquisition of businesses
Increase (Decrease) Through Business Acquisitions, Contingent Consideration
Increase (Decrease) Through Business Acquisitions, Contingent Consideration
Telix Targeting Technologies, Inc.
Telix Targeting Technologies, Inc. [Member]
Telix Targeting Technologies, Inc.
Accumulated losses
Retained earnings/(accumulated losses)
Retained earnings
Payment for provision of services in relation to business development
Amount incurred by entity for provision of key management personnel services provided by separate management entity
A 10% decrease in probability of success
10% Decrease In Probability Of Success [Member]
10% Decrease In Probability Of Success
Schedule of Consideration Paid
Disclosure of detailed information about business combination [text block]
Total employee benefit obligations
Provisions for employee benefits
Buildings
Buildings [member]
Types of risks [domain]
Types of risks [domain]
Lease Payments [Abstract]
Lease payments [Abstract]
Lease payments [Abstract]
Increase in trade and other receivables
Adjustments for decrease (increase) in trade and other receivables
Accrued royalties
Accrued Royalties Classified As Current
The amount of accrued royalties classified as current.
Telix Pharmaceuticals (NZ) Limited
Telix Pharmaceuticals (NZ) Limited [Member]
The name of the entity which is controlled by another entity.
Telix QSAM, Inc.
Telix QSAM, Inc. [Member]
The name of the entity which is controlled by another entity.
Subsidiaries [axis]
Subsidiaries [axis]
Trade and other payables
Trade And Other Payables As Of Acquisition Date
Trade And Other Payables As Of Acquisition Date
Interest paid
Interest paid, classified as operating activities
JPY
Japan, Yen
Settlement period of trade and other payables (in days)
Settlement Period Of Trade And Other Payables
The normal settlement period for trade and other payables, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Isotope raw materials
Non Current Isotope Raw Materials
Non Current Isotope Raw Materials
TLX591-Px (Illuccix®)
TLX591-Px (Illuccix) [Member]
TLX591-Px (Illuccix)
Lapsed/forfeited during the year (in shares)
Number of share options expired and forfeited in share-based payment arrangement
The number of share options expired and forfeited in a share-based payment arrangement.
Geographical areas [axis]
Geographical areas [axis]
Milestone achievement probability of success factor
Milestone Achievement Probability Of Success Factor [Member]
This member stands for milestone achievement probability of success factor used as a measurement input.
Leased plant and equipment
Leased Plant And Equipment [Member]
This member stands for leased plant and equipment.
Opening balance
Closing balance
Liabilities arising from financing activities
Tranche [Domain]
Tranche [Domain]
Tranche [Domain]
Shares issued through the exercise of share options and warrants
Shares Issued Through Exercise Of Share Options And Warrants
Value of shares issued as a result of the exercise of stock options and warrants.
Lease liabilities
Non-current
Non-current lease liabilities
Number of options issued under EIP [Abstract]
Number of options issued under equity incentive plan [Abstract]
Number of options issued under equity incentive plan [Abstract]
Deferred tax assets and liabilities [abstract]
Deferred tax assets and liabilities [abstract]
Revenue from contracts with customers
Disclosure of revenue from contracts with customers [text block]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Schedule of Deferred Tax Assets
Schedule of Disclosure of Deferred Tax Assets [Text Block]
Schedule of Disclosure of Deferred Tax Assets
Loan repayment period (in years)
Borrowings Holiday Period, Term
The repayment period of loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Long service leave
Provisions For Employee Benefits, Long Service Leave
The amount of non-current Long service leave employee benefit obligations.
Intangible assets other than goodwill
Intangible assets other than goodwill
Document Financial Statement Error Correction [Flag]
Document Financial Statement Error Correction [Flag]
Intellectual property
Intellectual Properties [Member]
This member stands for a class of intellectual properties.
Segments [domain]
Segments [domain]
Schedule of Trade and Other Receivables
Disclosure Of Detailed Information About Trade And Other Receivables Explanatory [Table Text Block]
The disclosure of detailed information about trade and other receivables.
Cash and cash equivalents
Cash and cash equivalents at the beginning of the financial year
Cash and cash equivalents at the end of the financial year
Cash and cash equivalents
Unallocated income, expenses and eliminations:
Unallocated amounts [member]
Quality costs
Quality Costs [Member]
Quality Costs
Document Information [Table]
Document Information [Table]
Contingent consideration
Current
Current Contingent Consideration
The amount of current contingent consideration.
Total deferred tax liabilities
Balance at the beginning
Balance at the end
Deferred Tax Liabilities Gross
Amount of deferred tax liabilities, before deferred tax liabilities attributable to taxable differences with provisions.
Lease liabilities
Lease liabilities
Lease Liabilities Recognized As Of Acquisition Date
The amount recognized as of the acquisition date for lease obligation assumed in a business combination.
Schedule of Transactions with Other Related Parties
Disclosure of transactions between related parties [text block]
Schedule of Borrowings
Disclosure of detailed information about borrowings [text block]
United States
USA
UNITED STATES
Exchange differences
Increase (decrease) through net exchange differences, other provisions
Beginning balance
Ending balance
Total contingent consideration
Contingent consideration
Contingent consideration, carrying amount
Contingent Consideration
Business acquisition amount of contingent consideration recognized.
Business combinations [axis]
Business combinations [axis]
Beginning balance
Ending balance
Total provisions
Provisions
Land and buildings
Properties
Land and buildings [member]
Business combinations [domain]
Business combinations [domain]
Acquisition of businesses
Acquisitions through business combinations, right-of-use assets
A 10% reduction in future cash inflows
10% Reduction In Future Cash Inflows [Member]
10% Reduction In Future Cash Inflows
Cost of inventories recognised as expense during period
Cost of inventories recognised as expense during period
Product and Service [Domain]
Product and Service [Domain]
Employee benefit obligations
Temporary differences in relation to employee benefit obligations
Employee Benefit Obligations [Member]
This member stands for employee benefit obligations.
RLS (USA), Inc.
RLS (USA) Inc [Member]
Name of the entity controlled by another entity.
Grand Pharmaceutical Group Limited [Member]
Grand pharmaceutical group limited [Member]
The Group entered into a strategic commercial partnership with Grand Pharmaceutical Group Limited (Grand Pharma or GP, formerly known as China Grand Pharma or CGP) for the Group's portfolio of targeted radiation products.
Total deferred tax assets
Balance at the beginning
Balance at the end
Deferred Tax Asset Gross
Amount of deferred tax assets, before deferred tax asset attributable to taxable differences with provisions.
Depreciation
Depreciation expense
Vested and exercisable (in AUD/USD per share)
Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement
The weighted average exercise price of share options vested and exercisable in a share-based payment arrangement.
Contingent consideration covenant, sales volumes and outstanding balance settled
Contingent Consideration Covenant, Sales Volumes And Outstanding Balance Settled
Contingent Consideration Covenant, Sales Volumes And Outstanding Balance Settled
Disclosure of attribution of expenses by nature to their function [table]
Disclosure of attribution of expenses by nature to their function [table]
Contractual Maturity of Financial Instrument Liabilities
Disclosure of maturity analysis for non-derivative financial liabilities [text block]
Lapsed during the year (in shares)
Number of share options expired in share-based payment arrangement
Schedule of Other Current Assets
Disclosure Of Detailed Information About Other Current Assets [Table Text Block]
The disclosure of detailed information about other current assets.
Payroll liabilities
Short-term employee benefits accruals
Schedule of Lease Payments
Disclosure Of Operating Lease Payments [Text Block]
The disclosure of information about operating lease liabilities.
Schedule of Employment Costs
Disclosure Of Detailed Information About Employment Costs [Text Block]
The disclosure of detailed information about employment costs.
Telix Pharmaceuticals (UK) Ltd
Telix Pharmaceuticals (UK) Ltd [Member]
The name of the entity which is controlled by another entity.
City Area Code
City Area Code
Schedule of Depreciation and Amortization
Schedule Of Disclosure of Depreciation And Amortization [Text Block]
Schedule Of Disclosure of Depreciation And Amortization
Contingent consideration
Description of accounting policy for contingent liabilities and contingent assets [text block]
Employment costs
Disclosure Of Employment Costs Explanatory [Text Block]
The entire disclosure for employment costs.
Charged to profit or loss
Contingent Consideration Charged To Profit Or Loss
The amount of contingent consideration charged to profit or loss during the year.
USD
United States of America, Dollars
Diluted earnings per share [abstract]
Diluted earnings per share [abstract]
Telix Pharmaceuticals Holdings Pty Limited
Telix Pharmaceuticals Holdings Pty Limited [Member]
The name of the entity which is controlled by another entity.
Telix Pharmaceuticals (Switzerland) GmbH
Telix Pharmaceuticals (Switzerland) GmbH [Member]
The name of the entity which is controlled by another entity.
Useful lives of assets (in years)
Useful life measured as period of time, property, plant and equipment
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table]
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table]
Radiopharmacy licenses
Fair Value Adjustment, Radio Pharmacy Licenses
Fair Value Adjustment, Radio Pharmacy Licenses
Over 5 years
Later than five years [member]
Related party transactions
Disclosure of related party [text block]
Share capital [Abstract]
Share Capital Reserve [Abstract]
Share capital reserve [Abstract]
Contribution to costs since acquisition, term
Contribution To Costs Since Acquisition, Term
Contribution To Costs Since Acquisition, Term
Non-Executive Directors’ fees
Non-Executive Directors Fees
The amount of fees paid or payable to Non-executive directors.
Level 3 of Fair Value Hierarchy
Level 3 of fair value hierarchy [member]
Deed of cross guarantee
Disclosure of Deed Of Cross Guarantee [Text Block]
Disclosure of Deed Of Cross Guarantee
Total
Income tax relating to components of other comprehensive income
Lightpoint
Lightpoint Medical [Member]
The name of the entity which is controlled by another entity.
Interest expense on lease liabilities
Interest expense
Interest expense on lease liabilities
Key judgments and estimates
Disclosure of accounting judgements and estimates [text block]
Share capital reserve
Beginning balance
Ending balance
Share capital reserve
Capital Reserve (Deficit)
A component of equity representing the capital reserves(deficit).
TLX591
TLX591-Tx [Member]
This member stands for clinical product used for therapeutic and diagnostic applications.
Schedule of Income Tax Expense/(Benefit)
Disclosure Of Detailed InformationAbout Income Tax Benefit Expense Explanatory [Table Text Block]
The disclosure of detailed information about income tax benefit (expense).
Goodwill
Goodwill recognised as of acquisition date
Schedule of Impact Of Possible Changes In Key Assumptions
Schedule of Impact Of Possible Changes In Key Assumptions [Table Text Block]
Schedule of Impact Of Possible Changes In Key Assumptions
Transfer on satisfaction of acquisition performance rights
Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights
Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights
Fair value remeasurement of contingent consideration
Adjustments For Fair Value Remeasurement Of Contingent Consideration
Adjustments for contingent consideration to reconcile profit (loss) to net cash flow from (used in) operating activities.
Telix Innovations SA
Telix Innovations SA [Member]
The name of the entity which is controlled by another entity.
Disclosure of classes of share capital [table]
Disclosure of classes of share capital [table]
Unobservable inputs [axis]
Unobservable inputs [axis]
Auditor Name
Auditor Name
Segment consolidation items [domain]
Segment consolidation items [domain]
Reconciliation of Total Segment Adjusted EBITDA and Group Adjusted EBITA to Profit/(Loss) Before Income Tax [Abstract]
Reconciliation Of Total Segment Adjusted EBITDA And Group Adjusted EBITA To Profit/Loss) Before Income Tax [Abstract]
Reconciliation of total segment adjusted EBITDA and group adjusted EBITA to profit/(loss) before income tax [Abstract]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Telix Pharmaceuticals (Germany) GmbH
Telix Pharmaceuticals (Germany) GmbH [Member]
The name of the entity which is controlled by another entity.
Other deposits and assets
Other Deposits And Assets, Noncurrent
Other Deposits And Assets, Noncurrent
Financial assets at FVOCI reserve [Abstract]
Financial assets at FVOCI reserve [Abstract]
Financial assets at FVOCI reserve [Abstract]
Trade and other receivables
Disclosure of trade and other receivables [text block]
Government grant liability
Government Grant Liability, Undiscounted Cash Flows
Government Grant Liability, Undiscounted Cash Flows
Deferred tax liabilities
Fair Value Adjustment, Deferred Tax Liability
Amount of increase (decrease) in deferred tax liabilities for fair value adjustment in a business combination.
FAP Targeting
FAP Targeting [Member]
FAP Targeting
Past due status [axis]
Past due status [axis]
Goodwill
Goodwill [member]
Term
Option life, share options granted
Net cash (used in)/from operating activities
Cash flows from (used in) operating activities
Finished goods
Current finished goods
Disclosure of terms and conditions of share-based payment arrangement [line items]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Working capital facility [Abstract]
Working capital facility [Abstract]
Working capital facility [Abstract]
Non-current liabilities
Non-current liabilities [abstract]
Share-based payments
Disclosure of share-based payment arrangements [text block]
Non-current financial assets
Description Of Accounting Policy For Non-Current Financial Assets [Policy Text Block]
The description of the entity's material accounting policy information for non-current financial assets.
Disclosure of detailed information about intangible assets [abstract]
Disclosure of detailed information about intangible assets [abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Adjustments for
Adjustments to reconcile profit (loss) [abstract]
Later than one year
Later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Reconciliation of changes in right-of-use assets [abstract]
Reconciliation of changes in right-of-use assets [abstract]
Schedule of Contingent Consideration
Schedule Of Contingent Consideration Explanatory [Text Block]
Tabular disclosure of information about contingent consideration.
Research and development costs
Disclosure of research and development expense [text block]
Motor vehicles
Motor vehicles
Motor vehicles [member]
Reclassifications
Reclassifications, Right-Of-Use Asset
The amount of reclassifications of right-of-use assets.
Government rebates payable
Current government grants
Supply chain costs
Supply Chain Costs [Member]
Supply Chain Costs
Payments for contingent consideration
Payments For Contingent Consideration, Classified As Operating Activities
The cash outflow for payments to contingent consideration, classified as operating activities.
Separate management entities [axis]
Separate management entities [axis]
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in other comprehensive income, after tax, assets
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in other comprehensive income, after tax, assets
Exercise price of incentive securities in exchange for forfeited securities (in dollars per share)
Exercise Price Of Incentive Securities In Exchange For Forfeited Securities
The exercise price of incentive securities in exchange for forfeited securities.
Grant date January 27, 2021
Grant Date January 27, 2021 [Member]
Grant Date January 27, 2021
Classes of other provisions [axis]
Classes of other provisions [axis]
Leasehold improvements
Leasehold improvements [member]
Investment in Atonco SAS
Atonco SAS [Member]
The name of the entity which is controlled by another entity.
Reconciling items
Material reconciling items [member]
Issue of convertible bonds
Issue of convertible instruments
Trade creditors
Current trade payables
Sensitivity Analysis
Sensitivity analysis for types of market risk [text block]
Key management personnel compensation
Key management personnel compensation
Number of shares issued [abstract]
Number of shares issued [abstract]
Receipts from customers
Receipts from sales of goods and rendering of services
Set-off of deferred tax liabilities pursuant to set-off provisions
Deferred Tax liabilities Pursuant To Set-Off Provisions
The increase (decrease) in deferred tax assets pursuant to set-off provisions.
Classes of current inventories [abstract]
Classes of current inventories [abstract]
Employee benefit obligations
Current Employee Benefit Obligations
The amount of current employee benefit obligations.
Finance cost [Abstract]
Finance cost [Abstract]
Finance cost [Abstract]
Operating Segment Assets and Liabilities [Abstract]
Operating segment assets and liabilities [Abstract]
Operating segment assets and liabilities [Abstract]
Disclosure of credit risk exposure [line items]
Disclosure of credit risk exposure [line items]
Schedule of Employee Benefit Obligations
Disclosure of defined benefit plans [text block]
Disclosure of maturity analysis for non-derivative financial liabilities [table]
Disclosure of maturity analysis for non-derivative financial liabilities [table]
Ordinary shares
Ordinary shares [member]
Remuneration of auditor
Disclosure of auditors' remuneration [text block]
Earnings per share
Disclosure of earnings per share [text block]
Gross carrying amount
Cost
Gross carrying amount [member]
Trade and other payables
Total trade and other payables
Trade and other payables, carrying amount
Trade and other current payables
Applicable tax rate
Applicable tax rate
Auditor's remuneration [abstract]
Auditor's remuneration [abstract]
Inventories
Disclosure of inventories [text block]
Schedule Of Disclosure of Deferred Tax Liabilities
Schedule Of Disclosure of Deferred Tax Liabilities [Text Block]
Schedule Of Disclosure of Deferred Tax Liabilities
Accruals
Accruals classified as current
Intangible assets
Description of accounting policy for intangible assets and goodwill [text block]
Plant and equipment
Plant And Equipment [Member]
Plant And Equipment
Local Phone Number
Local Phone Number
Percentage of options granted to PSARs (in percentage)
Share-Based Compensation Arrangement By Share-Based Payment Award, Options Granted Percentage
Percentage of share options granted to performance-based stock awards holders out of the target.
Due 1 year
Not later than one year [member]
Selling, general and administrative expense [abstract]
Selling, general and administrative expense [abstract]
Disclosure of detailed information about property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment [abstract]
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, before tax, liabilities
Trade and Other Payables
Disclosure Of Trade And Other Payables Explanatory [Text Block]
The tabular disclosure of information about trade and other payables.
ASX securities
ASX Securities [Member]
ASX Securities
Non-current
Non-current portion of non-current borrowings, by type [abstract]
Annual leave
Provisions For Employee Benefits, Annual Leave
The amount of current annual leave employee benefit obligations.
Amounts adjusted to property, plant and equipment
Increase (Decrease) In Other Provision Adjusted To Property Plant And Equipment
Amount of increase (decrease) in other provision adjusted to property plant and equipment.
Finance costs [Abstract]
Finance Costs [Abstract]
Finance costs [Abstract]
Intangible assets
Identifiable intangible assets recognised as of acquisition date
Remuneration of auditor
Auditor's remuneration
Transaction costs arising on convertible bonds issue (in shares)
Increase (Decrease) Through Transaction Costs Arising On Convertible Bonds Issue, Shares
The increase (decrease) in equity resulting from the transaction costs arising on Convertible Bonds Issue, shares.
Borrowings
Borrowings
Due later than one year
Non-current
Non-current portion of non-current borrowings
Increase in inventory
Adjustments for decrease (increase) in inventories
Cash paid
Cash transferred
Property, plant and equipment
Description of accounting policy for property, plant and equipment [text block]
Deferred payment
Deferred Consideration Recognised As Of Acquisition Date
Deferred Consideration Recognised As Of Acquisition Date
Total consideration
Total consideration
Consideration transferred, acquisition-date fair value
Current and non-current classification
Description Of Accounting Policy For Classification Of Assets And Liabilities [Policy Text Block]
The description of the entity's accounting policy for the basis for how the entity classifies assets and liabilities as current and non-current.
Proceeds from borrowings
Proceeds from borrowings, classified as financing activities
Principal element of lease payments
Cash outflow for leases
Payments of lease liabilities, classified as financing activities
Schedule of Convertible Bonds Carrying Amount and Fair Value
Disclosure Of Detailed Information About Carrying Amount And Fair Value Of Convertible Bonds [Table Text Block]
The disclosure of detailed information about carrying amount and fair value of convertible bonds.
Entity Voluntary Filers
Entity Voluntary Filers
Acquisition related costs
Acquisition Related Costs
Acquisition Related Costs
Other assurance services
Auditor's remuneration for tax services
Acquisitions
Disclosure of business combinations [text block]
Proportion of ownership interest in subsidiary
Proportion of ownership interest in subsidiary
Consideration
Consideration, Share Options Granted
The consideration of share options granted.
Plant, equipment and vehicles
Plant, Equipment and Vehicles [Member]
Plant, Equipment and Vehicles
Entity Registrant Name
Entity Registrant Name
Total basic (loss)/earnings per share attributable to the ordinary equity holders of the Company (in dollars per share)
Basic earnings (loss) per share
Foreign exchange (losses)/gains
Adjustments for unrealised foreign exchange losses (gains)
Weighted average number of ordinary shares used as the denominator in calculating diluted earnings/loss per share (in shares)
Weighted average number of ordinary shares used in calculating diluted earnings per share
Deferred tax asset
Fair Value Adjustment, Deferred Tax Assets
Fair Value Adjustment, Deferred Tax Assets
Foreign exchange translation gains
Tax Effect Of Exchange Translation Loss
The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to exchange translation loss.
Classes of intangible assets other than goodwill [domain]
Classes of intangible assets other than goodwill [domain]
Disclosure of associates [table]
Disclosure of associates [table]
Employee benefit obligations
Non-Current Employee Benefit Obligations
The non-current portion of non-current employee benefit obligations.
Share-based payments
Adjustments for share-based payments
Decrease/(increase) in other non-current assets
Adjustments For Decrease (Increase) In Other Non-Current Assets
Adjustments for decrease (increase) in other non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities.
Temporary differences in relation to provisions
Provisions [Member]
This member stands for provisions.
Miscellaneous current assets [abstract]
Miscellaneous current assets [abstract]
Major components of tax expense (income) [abstract]
Major components of tax expense (income) [abstract]
Charges/(credit) on acquisition
Deferred Tax Liability On Acquisition
The amount of tax expense or income relating to changes in deferred tax liabilities recognized on acquisition.
Segment consolidation items [axis]
Segment consolidation items [axis]
Employee benefit obligations
Disclosure of employee benefits [text block]
Maturity date
Borrowings Maturity, Term
The maturity term of borrowings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Schedule of Intangible Assets
Disclosure of reconciliation of changes in intangible assets and goodwill [text block]
Unwind of discount
Unwind Of Discount
The amount of unwind of discount in finance cost.
All Currencies [Domain]
All Currencies [Domain]
Equity
Equity [abstract]
Disclosure of disaggregation of revenue from contracts with customers [table]
Disclosure of disaggregation of revenue from contracts with customers [table]
Disclosure of detailed information about financial instruments [abstract]
Disclosure of detailed information about financial instruments [abstract]
Commercial
Commercial [Member]
Commercial
Disclosure of operating segments [abstract]
Disclosure of operating segments [abstract]
Acquisition term (in years)
Business Acquisition, Consideration Term
The term of the note issued for consideration payable for the acquisition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Performance rights issued
Performance Rights Issued As Of Acquisition Date
The fair value of performance rights issued by acquiree in the consideration at the date of acquisition.
Unrealized foreign exchange gains
Unrealised foreign exchange gains (losses) [member]
Disclosure of transactions between related parties [abstract]
Disclosure of transactions between related parties [abstract]
ADS-backed securities
ADS-Backed Securities [Member]
ADS-Backed Securities
Subclassifications of assets, liabilities and equities [abstract]
Decrease/(increase) in other current assets
Adjustments for decrease (increase) in other current assets
Additions
Additions other than through business combinations, intangible assets other than goodwill
General and administration costs
Disclosure of general and administrative expense [text block]
Market approach
Market approach [member]
Trade and other payables
Trade and other payables, undiscounted cash flows
Second Tranche
Second Tranche [Member]
Second Tranche
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Classes of employee benefits expense [abstract]
Classes of employee benefits expense [abstract]
Provision for obsolescence
Provision For Obsolescence
A classification of current inventory representing the amount of provision for obsolescence.
Issue of convertible bonds (in shares)
Increase (Decrease) Through Issue Of Convertible Bonds
The change in equity resulting from the issuing of convertible bonds.
Disclosure of temporary difference, unused tax losses and unused tax credits [table]
Disclosure of temporary difference, unused tax losses and unused tax credits [table]
Parent
Parent [member]
Lease payments (principal and interest)
Cash outflow for leases
Grant Date January 1, 2025
Grant Date January 1, 2025 [Member]
Grant Date January 1, 2025
A 50% reduction in terminal growth rate
50% Reduction In Terminal Growth Rate [Member]
50% Reduction In Terminal Growth Rate
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [line items]
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [line items]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table]
Auditor Firm ID
Auditor Firm ID
Superannuation entitlements
Key management personnel compensation, post-employment benefits
Types of contracts [axis]
Types of contracts [axis]
Bonuses
Provisions For Employee Benefits, Bonusses
Provisions For Employee Benefits, Bonusses
Disclosure of contingent liabilities [abstract]
Disclosure of contingent liabilities [abstract]
Deferred tax asset
Deferred Tax Asset [Member]
Deferred Tax Asset
Schedule of Revenue from Sale and Transfer of Goods and Services
Disclosure of disaggregation of revenue from contracts with customers [text block]
Owners of Telix Pharmaceuticals Limited
Total comprehensive loss for the year
Comprehensive income, attributable to owners of parent
Upfront cash consideration
Upfront Cash Consideration
The amount of upfront cash consideration to share of profits generated from QDOSE sales and a referral fee on deals.
Unallocated income, expenses and eliminations:
Unallocated income, expenses and eliminations [Abstract]
Unallocated income, expenses and eliminations [Abstract]
Change In Risk Variable [Domain]
Change In Risk Variable [Domain]
Change In Risk Variable [Domain]
Grant date April 26, 2024
Grant Date April 26, 2024 [Member]
This member stands for a classification of grant date share based payment.
Exchange differences
Increase (Decrease) Through Net Exchange Differences, Contingent Consideration
Increase (Decrease) Through Net Exchange Differences, Contingent Consideration
Net loss of acquiree since acquisition date
Profit (loss) of acquiree since acquisition date
Total liabilities
Total liabilities
Liabilities
AUD
Australia, Dollars
Government grants
Description of accounting policy for government grants [text block]
Capital and reserves (in percent)
Borrowings Covenant, Percentage Of Capital And Reserves Which Cumulative Losses Should Not Exceed
Borrowings Covenant, Percentage Of Capital And Reserves Which Cumulative Losses Should Not Exceed
Investment in sub-leases
Investment In Sub-Leases, Non-current
Investment In Sub-Leases, Non-current
Grant Date October 17, 2024
Grant Date October 17, 2024 [Member]
Grant Date October 17, 2024
Contingent or deferred consideration
Contingent consideration
Contingent consideration recognised as of acquisition date
Current tax payable
Current tax liabilities, current
Number of distributors
Significant Credit Risk Exposure, Number Of Distributors
Represents the number of distributors during the period.
Risk adjusted discount rate (in percent)
Discount rate applied to cash flow projections
Exchange differences
Increase (decrease) through net exchange differences, property, plant and equipment
Disclosure of information for cash-generating units [table]
Disclosure of information for cash-generating units [table]
Convertible bond interest expense
Interest expense
Interest expense on bonds
Disclosure of nature and extent of risks arising from financial instruments [table]
Disclosure of nature and extent of risks arising from financial instruments [table]
Lease liabilities
Temporary differences in relation to lease liabilities
Lease liabilities [member]
Threshold sales percentage for first approval (in percent)
Contingent Consideration Covenant, Percentage Of Net Sales
Contingent Consideration Covenant, Percentage Of Net Sales
Shares issued through the exercise of share options and warrants (in shares)
Increase (Decrease) Shares Issued Through Exercise Of Share Options And Warrants
Shares issued as a result of the exercise of stock options and warrants.
Future variable payments (in years)
Future Variable Payments
The period for future variable payments, which are calculated based on a percentage of net sales, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Fair value
Financial liabilities, at fair value
Options issued under EIP
Expense from equity-settled share-based payment transactions
Current tax expense
Current tax expense (income)
1-5 years
Later than one year and not later than five years [member]
Valuation techniques used in fair value measurement [domain]
Valuation techniques used in fair value measurement [domain]
Going concern
Description Of Accounting Policy For Going Concern [Policy Text Block]
The description of the entity's accounting policy for going concern.
Top of range
Top of range [member]
Due within one year
Current Borrowings Over Payments
Current Borrowings Over Payments
Research and development costs
Research and development costs
Research and development costs
Research and development expense
Total other non-current assets
Total other non-current assets
Other non-current assets
Other non-current assets
Current year tax losses not recognized
Tax effect of tax losses
Global manufacturing costs
Global Manufacturing Costs [Member]
Global Manufacturing Costs
Other countries
Foreign countries [member]
Inventories
Description of accounting policy for measuring inventories [text block]
Non-current assets by location of asset
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]
Inventory Type [Domain]
Inventory Type [Domain]
Inventory Type [Domain]
Borrowings by name [domain]
Borrowings by name [domain]
60 days
Later than two months and not later than three months [member]
Foreign currency risk
Currency risk [member]
Trade receivables
Trade receivables [member]
Unwind of discount
Adjustments For Unwind Of Discount
Adjustments for unwind of discount to reconcile profit (loss) to net cash flow from (used in) operating activities.
Revenue from contracts with customers
Revenue by location of customer
Revenue from contracts with customers
Deferred tax liabilities
Net deferred tax liabilities
Deferred tax liabilities
Manufacturing and distribution costs
Manufacturing and distribution costs
Manufacturing and distribution costs
Manufacturing And Distribution Costs
The amount of expense relating to manufacturing and distribution of goods and services of the entity.
Income taxes paid
Income taxes paid
Income taxes paid (refund), classified as operating activities
Other comprehensive (loss) / income
Other comprehensive (loss)/income
Revaluation - gross
Other comprehensive income
Classes of liabilities [axis]
Classes of liabilities [axis]
Past due status [domain]
Past due status [domain]
Total identifiable assets and liabilities
Identifiable assets acquired (liabilities assumed)
Net (decrease)/increase in cash held
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
Types of share-based payment arrangements [axis]
Types of share-based payment arrangements [axis]
Depreciation and amortization
Adjustments for depreciation and amortisation expense
Telix Pharmaceuticals (France) SAS
Telix Pharmaceuticals (France) SAS [Member]
The name of the entity which is controlled by another entity.
Recognized income tax benefit
Unused Tax Losses And Credits For Which Deferred Tax Asset Is Recognised
Unused Tax Losses And Credits For Which Deferred Tax Asset Is Recognised
Title of 12(b) Security
Title of 12(b) Security
Equity issued
Equity interests of acquirer
Schedule of Unrecognized Deferred Tax Assets
Schedule Of Unrecognized Deferred Tax Assets [Table Text Block]
The disclosure of unrecognized deferred tax assets.
Issue of shares on acquisitions
Shares issued
Issue of equity
Borrowings
Bank borrowings, undiscounted cash flows
Telix Innovations Rph Participacoes Ltda
Telix Innovations Rph Participacoes Ltd [Member]
The name of the entity which is controlled by another entity.
Schedule of Other (Gains)/Losses (net)
Disclosure Of Other (Losses) Gains, Net [Text Block]
The tabular disclosure of other (losses) gains net.
Payments for contingent consideration
Purchase Of Contingent Consideration, Classified As Investing Activities
The cash outflow for the purchase of contingent consideration, classified as investing activities.
Lightpoint Surgical Spain S.L. (Lightpoint Medical Espana SLU)
Lightpoint Surgical Spain S.L. (Lightpoint Medical Espana SLU) [Member]
The name of the entity which is controlled by another entity.
Other auditors and their related network firms
Other Auditors And Their Related Network Firms [Member]
This member stands for other auditors and their related network firms.
Bank loans
Bank Loans [Member]
The member stands for Bank Loans.
Attribution of expenses by nature to their function [domain]
Attribution of expenses by nature to their function [domain]
Schedule of Numerical Reconciliation of Prima Facie Tax Payable to Income Tax Expense/(Benefit)
Disclosure Of Detailed Information About Numerical Reconciliation Of Prima Facie Tax Payable To Income Tax Benefit Expense Explanatory [Table Text Block]
The disclosure of detailed information about the numerical reconciliation of prima facie tax payable to income tax benefit.
Additions to non-current assets
Additions to non-current assets other than financial instruments, deferred tax assets, net defined benefit assets, and rights arising under insurance contracts
Investment in IRMA Surgical Pty Ltd
IRMA Surgical [Member]
IRMA Surgical
Subsidiaries [domain]
Subsidiaries [domain]
Intangible assets
Temporary differences in relation to intangible assets
Intangible Assets [Member]
This member stands for intangible assets.
Repayment of borrowings
Repayments of borrowings, classified as financing activities
Commitments and contingencies [Line Items]
Commitments And Contingencies [Line Items]
Line items represent concepts of commitments.
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]
Ageing of Trade Receivables
Disclosure of credit risk exposure [text block]
Borrowings by name [axis]
Borrowings by name [axis]
Raw materials and stores
Current raw materials and current production supplies
Maximum deferred payment
Maximum Deferred Consideration Recognised As Of Acquisition Date
Maximum Deferred Consideration Recognised As Of Acquisition Date
Remeasurement of provisions
Gains (Losses) Through Remeasurement Of Other Provisions
The increase (decrease) in other provisions resulting from remeasurement of provision.
Trade and other payables
Disclosure of trade and other payables [text block]
Working capital
Working Capital [Member]
Working Capital
Telix ARTMS Inc.
Telix ARTMS Inc. [Member]
The name of the entity which is controlled by another entity.
Schedule of Classes of Share Capital
Disclosure of classes of share capital [text block]
Schedule of Research and Development Costs
Disclosure Of Detailed Information About Research And Development Costs Explanatory [Text Block]
The disclosure of detailed information about research and development costs.
Borrowings
Description of accounting policy for borrowings [text block]
Allowance for impairment losses
Expected credit losses
Accumulated impairment [member]
ARTMS US, Inc.
ARTMS US, Inc. [Member]
The name of the entity which is controlled by another entity.
Financial assets
Disclosure of financial instruments [text block]
Deferred tax liabilities
Deferred Tax Liability [Member]
Deferred Tax Liability
Schedule of Other Reserves and Share Capital Reserve
Disclosure of reserves within equity [text block]
Schedule of Property, Plant and Equipment
Disclosure of detailed information about property, plant and equipment [text block]
Licenses
Licences [member]
Telix Pharmaceuticals (Canada) Inc.
Telix Pharmaceuticals (Canada) Inc. [Member]
The name of the entity which is controlled by another entity.
Borrowings, interest rate (in percent)
Borrowings, interest rate
Changes in provisions
Increase (Decrease) Through Changes in Provisions, Intangible Assets And Goodwill
The increase (decrease) in intangible assets other than goodwill resulting from changes in provision.
Schedule of Provisions
Disclosure Of Information About Provisions [Text Block]
Tabular disclosure of information about provisions.
Net cash used in investing activities
Cash flows from (used in) investing activities
Inventories
Inventory recognised as of acquisition date
Commitments [Abstract]
Commitments [Abstract]
Commitments [Abstract]
Las Vegas Radiopharmacy, Inc.
Las Vegas Radiopharmacy, Inc. [Member]
Las Vegas Radiopharmacy, Inc.
Disclosure of detailed information about intangible assets [line items]
Disclosure of detailed information about intangible assets [line items]
Commitments and contingencies [Table]
Commitments And Contingencies [Table]
Commitments and contingencies [Table]
Financial assets
Non-current financial assets
Unallocated employment costs
Total employment costs
Employee benefits expense
Maximum deposit term
Other Financial Assets, Maximum Deposit Term
Other Financial Assets, Maximum Deposit Term
Amortization charge
Amortisation, intangible assets other than goodwill
Proceeds from issue of shares and other equity
Proceeds from issuing other equity instruments
Patents
Copyrights, patents and other industrial property rights, service and operating rights [member]
Total current assets
Current assets
Current assets
Capital commitments
Contractual capital commitments
Net sales price per unit
Net Sales Price Per Unit [Member]
This member stands for net sales price per unit used as a measurement input.
Options
Share options [member]
ImaginAb
ImaginAb Inc [Member]
ImaginAb Inc
Disclosure of operating segments [table]
Disclosure of operating segments [table]
Credited/(charged) to profit and loss
Deferred tax expense (income) recognised in profit or loss
Over time
Goods or services transferred over time [member]
Volume weighted average period
Volume Weighted Average Period
Volume weighted average period in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Segments [axis]
Segments [axis]
Types of risks [axis]
Types of risks [axis]
Charges/(credit) to profit and loss
Deferred Tax Liability Deferred Tax Expense Income Recognized In Profit Or Loss
The amount of tax expense or income relating to changes in deferred tax liabilities recognized in profit or loss.
Trade and other payables [abstract]
Trade and other payables [abstract]
Disclosure of transactions between related parties [table]
Disclosure of transactions between related parties [table]
Depreciation charge
Depreciation, property, plant and equipment
Exercised during the year (in AUD/USD per share)
Exercise price (in AUD/USD per share)
Weighted average exercise price of share options exercised in share-based payment arrangement
Current tax asset
Current tax assets, current
Attribution of expenses by nature to their function [axis]
Attribution of expenses by nature to their function [axis]
Volatility
Expected volatility, share options granted
Current
Current provisions for employee benefits
Share price (in dollars per share)
Par value per share
Property, plant and equipment
Disclosure of property, plant and equipment [text block]
ARTMS
ARTMS [Member]
This member stands for a product or business unit.
Dividend yield
Expected dividend as percentage, share options granted
Amendment Flag
Amendment Flag
Tranche two
Tranche Two [Member]
Tranche Two
Components of equity [domain]
Components of equity [domain]
Separate management entities [domain]
Separate management entities [domain]
Disclosure of operating segments [line items]
Disclosure of operating segments [line items]
Contract liabilities
Disclosure of contract liabilities explanatory [Text Block]
The entire disclosure for contract liabilities.
IsoTherapeutics
IsoTherapeutics
IsoTherapeutics [Member]
This member stands for a product or business unit.
Employee benefits
Description of accounting policy for employee benefits [text block]
Additions
Increase through new leases, liabilities arising from financing activities
Telix Optimal Tracers, LLC
Telix Optimal Tracers, LLC [Member]
The name of the entity which is controlled by another entity.
Temporary difference, unused tax losses and unused tax credits [axis]
Temporary difference, unused tax losses and unused tax credits [axis]
Schedule of Reconciliation of (Loss)/Profit After Income Tax to Net Cash (Used in)/From Operating Activities
Disclosure Of Reconciliation Of Profit (Loss) After Income Tax To Net Cash From (Used In) Operating Activities [Text Block]
The disclosure of the reconciliation of profit (loss) after income tax to net cash from (used in) operating activities.
Telix IsoTherapeutics Group, Inc.
Telix IsoTherapeutics Group, Inc. [Member]
The name of the entity which is controlled by another entity.
Provision utilized
Provision used, other provisions
Range [domain]
Range [domain]
Telix Pharmaceuticals Australia Holdings Pty Ltd
Telix Pharmaceuticals Australia Holdings Pty Limited [Member]
The name of the entity which is controlled by another entity.
Deduct trade and other payables capitalized to intangible assets
Adjustments for increase (decrease) in trade and other payables
Contingent consideration
Contingent Consideration Liability, Undiscounted Cash Flows
Contingent Consideration Liability, Undiscounted Cash Flows
Profit/(loss)
Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings
Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings
Disclosure of Information for Cash-Generating Units
Disclosure of information for cash-generating units [text block]
Continuing operations
Comprehensive Income From Continuing Operations [Abstract]
Comprehensive income from continuing operations [Abstract]
Auditors of the Group - PricewaterhouseCoopers Australia and related network firms
Pricewaterhouse Coopers Australia And Related Network Firms [Member]
This member stands for Auditors of the Group - Pricewaterhouse Coopers Australia and related network firms providing auditing services.
Revenue recognized
Revenue that was included in contract liability balance at beginning of period
TLX66-CDx
TLX66-C Dx [Member]
This member stands for a cash-generating unit.
Grant date November 30, 2023
Grant Date November 30, 2023 [Member]
Grant Date November 30, 2023
Total
Expense from share-based payment transactions
Cash transferred upon signing
Cash Transferred Upon Signing
Cash Transferred Upon Signing
Change In Risk Variable [Axis]
Change In Risk Variable [Axis]
Change In Risk Variable
Disclosure of products and services [table]
Disclosure of products and services [table]
Share-based payments expense & Employee Share Trust payments
Tax Effects Of Share-Based Payments Expense And Employee Share Trust Payments
Tax Effects Of Share-Based Payments Expense And Employee Share Trust Payments
IMBC Group
IMBC Group [Member]
The name of financial institution which company made an first loan agreement.
Address Type [Domain]
Address Type [Domain]
Borrowings
Face value of convertible bonds issued
Notional amount
An increase of 2.5% in post-tax discount rate
2.5% Increase In Post-Tax Discount Rate [Member]
2.5% Increase In Post-Tax Discount Rate
Contingent consideration
Disclosure of contingent consideration explanatory [Text Block]
The entire disclosure of contingent consideration during the year.
Other reserves [Abstract]
Other reserves [Abstract]
Other reserves [Abstract]
Lease liabilities
Current
Current lease liabilities
Sales of goods, credit term (in days)
Sales Of Goods, Credit Term
The credit term for sale of goods, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Share-based payments associated with acquisitions
Increase (Decrease) Through Share-Based Payment Transactions Associated With Acquisitions, Equity
The increase (decrease) in equity resulting from share-based payment transactions associated with acquisitions.
Right-of-use assets
Description Of Accounting Policy For Right-Of-Use Assets [Policy Text Block]
The description of the entity's material accounting policy information for right-of-use assets.
Currency [Axis]
Currency [Axis]
Total diluted (loss)/earnings per share attributable to the ordinary equity holders of the Company (in dollars per share)
Diluted earnings (loss) per share
Schedule of Estimated Based on Contractual Obligations
Disclosure Of Commitments, Contractual Obligations Explanatory [Table Text Block]
The tabular disclosure commitments estimated based on the contractual obligations.
Maturity [domain]
Maturity [domain]
Schedule of Principal Subsidiaries
Disclosure of subsidiaries [text block]
Schedule of Manufacturing and Distribution Costs
Schedule Of Manufacturing And Distribution Costs [Table Text Block]
Schedule Of Manufacturing And Distribution Costs
Parent entity financial information
Disclosure of information about separate financial statements [text block]
Other non-current liabilities
Other Non-Current Liabilities, Undiscounted Cash Flows
Other Non-Current Liabilities, Undiscounted Cash Flows
Key management personnel compensation
Key Management Personnel Compensation [Abstract]
Key management personnel compensation [Abstract]
Grant date July 27, 2021
Grant Date July 27, 2021 [Member]
Grant Date July 27, 2021
Disclosure of terms and conditions of share-based payment arrangement [table]
Disclosure of terms and conditions of share-based payment arrangement [table]
Detailed information about contingent consideration [Line Items]
Detailed Information About Contingent Consideration [Line Items]
Detailed information about contingent consideration [Line Items]
Disclosure of reconciliation of liabilities arising from financing activities [table]
Disclosure of reconciliation of liabilities arising from financing activities [table]
Grant Date [Axis]
Grant Date [Axis]
Grant Date
Schedule of Earnings Per Share
Earnings per share [text block]
TLX090-Tx
TLX090-Tx [Member]
TLX090-Tx
Disclosure of associates [line items]
Disclosure of associates [line items]
Disclosure of detailed information about property, plant and equipment [table]
Disclosure of detailed information about property, plant and equipment [table]
Purchases of intangible assets
Purchase of intangible assets, classified as investing activities
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]
Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]
Cash flow information [Abstract]
Cash Flow Information [Abstract]
Cash flow information [Abstract]
Zircaix
Zircaix [Member]
Zircaix